Stocks had a Fine Finish to a Rough Week
Recap - After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.4%, the lowest since 2008, and a … Continue Reading
Read nowSearch Results for gene therapy
A Review of Our Latest Biotech Investing Ideas
Research - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
Premium
One Cool Datapoint for Battered Healthcare Investors
Recap - The biotech sector slipped all week before some green into Friday’s close. These dips are beginning to feel like the norm, though with every fresh … Continue Reading
Read now
Celladon’s Sweeping Impact on Biotech
Research - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read nowOur Top Stories from this Week in Healthcare
Insights - The talk of a bubble in biotech seems to have subsided (temporarily, no doubt), and the sector-tracking iShares Nasdaq Biotech ETF (IBB) has continued higher … Continue Reading
Read now
uniQure Dips on New Risk Disclosure
Research - It was just 5 days ago that Bristol-Myers Squibb (BMY) partnered with uniQure (QURE) on the discovery and development of novel gene therapies for cardiovascular … Continue Reading
Read now
uniQure Fills in the Missing Piece with Bristol-Myers Collaboration
Research - Great news for our suggested uniQure (QURE) position – Bristol-Myers Squibb (BMY) is putting up $100 million upfront to partner with the European gene therapy developer … Continue Reading
Premium